Matthew Strobeck

Provides diagnostic healthcare solutions

Develops vitro diagnostics solutions

Westfield utilizes an in-depth, fundamental research process, managing domestic growth equity products across the market capitalization spectrum to service their clients' diverse investment needs. The firm favors investing in earnings growth stocks given their conviction that stock prices follow earnings progress and that they offer the best opportunity for superior real rates of return. As a fundamental, bottom-up manager, macro-economic forecasts do not drive their stock selection process but do help to shape their investment themes.

Thomas Weisel Asset Management (TWAM) offers US equity separately managed accounts in small-cap growth, small/mid-cap growth and mid-cap growth strategies. The firm's investment approach is based on the idea that investors inefficiently price growth stocks because they over-extrapolate near-term trends in company fundamentals. Their investment selection process is based on fundamental research and a systematic valuation discipline. TWAM seeks to actively manage risk/reward trade-offs across securities and sectors to provide a more efficient allocation of portfolio capital. Their strategies employ in-depth fundamental research and a bottom-up stock selection process to create optimized portfolios of US growth stocks. The firm's small-cap strategy is offered as a separately managed account and through commingled funds. The strategy focuses on investments in the stocks of small US companies with a market-cap of $50 million to $5 billion. The strategy is benchmarked against the Russell 2000 Growth Index. TWAM's small/mid-cap strategy is offered as a separately managed account. The strategy focuses on investments ion the stocks of US small and mid-sized companies with a market-cap of $50 million to $10 billion. The strategy is benchmarked against the Russell 2500 Growth Index. Their mid-cap strategy is offered as a separately managed account. The strategy focuses on investments in the stocks of US mid-sized companies with a market-cap of $1 billion to $25 billion. The strategy is benchmarked against the Russell Mid-Cap Growth Index. Though not limited by sector, TWAM tends to invest in the stocks of companies in the technology services, healthcare technology, electronic technology, industrial services and finance sectors. The firm maintains a high turnover rate.

Engages in acquiring, developing and commercializing pharmaceutical products for the treatment of upper & lower gastrointestinal diseases and disorders

Operates as an agricultural bioscience company that focused on commercializing sustainable products

Develops and commercializes medical devices and biomaterial technology

Provides diagnostic research and clinical trial testing services & engages in discovery, development and commercialization of therapeutics

Develops skincare therapies